MW-assisted Er (OTf) 3-catalyzed mild cleavage of isopropylidene acetals in Tricky substrates

A Procopio, M Gaspari, M Nardi, M Oliverio, R Romeo - Tetrahedron Letters, 2008 - Elsevier
MW-assisted Er(OTf)3-catalyzed mild cleavage of isopropylidene acetals in Tricky substrates -
ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books Search …

Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients

J Burgos, M Crespo, V Falcó, A Curran… - Journal of …, 2012 - academic.oup.com
Objectives To assess the effectiveness of simplification to a dual antiretroviral regimen
containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced HIV-1 …

Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy

I Pellegrin, A Caumont, I Garrigue… - The Journal of …, 2003 - academic.oup.com
Of 75 human immunodeficiency virus (HIV) type 1–infected patients successfully responding
to 2 nucleoside reverse-transcriptase inhibitors (NRTIs) plus 1 protease inhibitor (PI), 55 …

A risk-benefit assessment of HIV protease inhibitors

GJ Moyle, BG Gazzard - Drug Safety, 1999 - Springer
The use of triple therapy regimens, often called highly active antiretroviral therapy (HAART),
generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been …

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine

EH Gisolf, S Jurriaans, J Pelgrom, F Van Wanzeele… - Aids, 2000 - journals.lww.com
Objective To evaluate the effect of treatment with ritonavir (RTV)/saquinavir (SQV)/stavudine
(D4T) or RTV/SQV alone, with treatment intensification if needed, in protease inhibitor-and …

HIV disease treatment in the era of HAART

P Bonfanti, A Capetti, G Rizzardini - Biomedicine & pharmacotherapy, 1999 - Elsevier
In the last three years basic science and clinical research have radically changed the
therapeutical approach to HIV disease. Recent guidelines suggest that treatments to HIV …

Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia

M Clerici, E Seminari, F Suter, F Castelli, A Pan… - Aids, 2000 - journals.lww.com
Background Suppression of human immunodeficiency virus (HIV) replication can be
obtained in chronically infected individuals by highly active antiretroviral therapy (HAART) …

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients

KE Squires, B Young, E DeJesus, N Bellos… - HIV Clinical …, 2010 - Taylor & Francis
Purpose: The ARIES study assessed safety and efficacy of an induction regimen with
atazanavir/ritonavir (ATV/RTV)+ abacavir/lamivudine (ABC/3TC) followed by simplification to …

Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults

J van der Lugt, RS Autar, S Ubolyam… - Journal of …, 2008 - academic.oup.com
Objectives To study the pharmacokinetics and short-term efficacy of low and standard dose
lopinavir/ritonavir and saquinavir combinations in Thai, human immunodeficiency virus (HIV) …

Latent reservoirs for HIV-1

J Blankson, D Persaud, RF Siliciano - Current opinion in infectious …, 1999 - journals.lww.com
Combination therapy for HIV-1 infection can reduce viremia to undetectable levels,
suggesting that prolonged treatment might eradicate the infection. However, one potential …